CD274 and peritoneum cancer: Recurrent ovarian, fallopian tube or primary peritoneal cancer.Bevacizumab and chemotherapy (PLD or paclitaxel) plus Atezolizumab (Tecentriq) (anti-PD-L1 mAb) or placebo.Randomised, triple-blind.